Every 8-K that Context Therapeutics Inc. (CNTX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow CNTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CNTX filings page.
Context Therapeutics Inc. is presenting an updated corporate overview focused on T cell engager bispecific antibodies for solid tumors, led by CTIM-76 (CLDN6 x CD3) and CT-202 (Nectin-4 x CD3). Both targets are highly expressed across multiple cancers with sizable relapse/refractory patient populations.
Early Phase 1a data for CTIM-76 in heavily pretreated platinum-resistant ovarian cancer (PROC) show a 29% confirmed overall response rate and 57% disease control rate in RECIST-evaluable patients at target doses, with tumor shrinkage across multiple lesions. Safety data show only Grade 1 cytokine release syndrome in a small number of patients, no Grade ≥2 events, and no dose reductions or discontinuations.
Preclinical and non-human primate studies for CT-202 demonstrate pH-dependent, tumor-selective T cell activation, complete tumor regressions in xenograft models, and high tolerated doses with pharmacokinetics supporting Q2W or Q3W dosing. The company guides to CT-202 first-patient-in during Q3 2026, CTIM-76 Q3W Phase 1a data in Q2 2027, CTIM-76 Phase 1b initiation in Q1 2027, and an expected cash runway into Q4 2027.
Context Therapeutics Inc. reports that on July 29, 2026 it received a written notice from Nasdaq stating its common stock is not in compliance with Nasdaq Listing Rule 5550(a)(2), the Minimum Bid Price Rule, because the closing bid price was below $1.00 per share for 30 consecutive business days.
The company has an initial 180-day grace period, until January 25, 2027, to regain compliance by having its stock close at or above $1.00 for at least 10 consecutive business days, with Nasdaq able to extend that 10-day window. If needed, the company may seek a second 180-day compliance period, subject to meeting other Nasdaq Capital Market listing standards and notifying Nasdaq of its intent to cure the deficiency.
If compliance is not restored within the allowed periods, Nasdaq may move to delist the shares, a decision the company could appeal to a Nasdaq Hearings Panel. Context Therapeutics states it will monitor its bid price and evaluate options, while cautioning there is no assurance it will regain compliance.
Context Therapeutics Inc. reported the results of its Annual Meeting of Stockholders held on June 24, 2026. Stockholders approved an amendment to the Amended and Restated Certificate of Incorporation to increase authorized common shares from 200,000,000 to 300,000,000, expanding the company’s capacity to issue stock in the future.
As of the April 27, 2026 record date, 91,879,177 common shares were outstanding, and 72,830,990 shares, or approximately 79.27%, were represented, establishing a quorum. Seven director nominees were elected, and CohnReznick LLP was ratified as independent registered public accounting firm for the fiscal year ending December 31, 2026. Stockholders also approved the potential adjournment of the meeting to solicit additional proxies for the charter amendment, although an adjournment ultimately was not needed.
Context Therapeutics Inc. reported positive interim Phase 1 results for CTIM-76, a Claudin 6 x CD3 T cell engager, in advanced platinum-resistant ovarian cancer. Among efficacy-evaluable patients at active doses of 140–280µg, 29% achieved confirmed partial responses and 57% achieved disease control, despite a median of 7 prior therapies and high prior exposure to antibody-drug conjugates.
Safety data showed predominantly low-grade, manageable side effects, with cytokine release syndrome limited to Grade 1 in 11% of PROC patients at active doses and no higher-grade CRS reported there. Pharmacokinetic data support moving from weekly to every-three-week dosing in the second half of 2026, and CTIM-76 has received FDA Fast Track Designation in PROC.
The company also highlighted a broader pipeline of T cell engagers targeting mesothelin (CT-95) and Nectin-4 (CT-202), large estimated addressable markets across multiple solid tumors, and an expected cash runway into mid-2027, positioning it to pursue further dose expansion and combination strategies.
Context Therapeutics Inc. has amended its license agreement with BioAtla for CT-202, its Nectin-4 x CD3 T cell engaging bispecific antibody. The company will pay BioAtla $4.5 million within five business days of May 14, 2026 and another $2.0 million by August 1, 2026. In return, Context’s exclusive licenses to the CT-202 and related antibodies become irrevocable, royalty-free, fully paid-up and non-terminable, and BioAtla loses termination rights. BioAtla will no longer receive milestone payments or royalties on these antibodies, giving Context full economic upside as it plans to start a Phase 1 CT-202 trial in the third quarter of 2026.
Context Therapeutics Inc. reports the resolution of a Delaware stockholder class action challenging parts of its charter. The Court of Chancery previously determined that charter provisions giving directors three-year terms and removal only for cause were invalid, and the company filed a Certificate of Correction to remove them.
Under a new letter agreement, a third-party service provider paid a $850,000 Mootness Fee to plaintiff’s counsel in full on the company’s behalf. The Court then granted an order closing the case, which will formally end after the Court is informed a quorum was achieved at the 2026 annual stockholders’ meeting scheduled for June 24, 2026.
Context Therapeutics Inc. reported that the FDA has granted Fast Track designation to CTIM-76, its investigational Claudin 6 x CD3 T cell engaging bispecific antibody, for treating platinum-resistant ovarian cancer in patients who have received all standard therapies.
CTIM-76 is being studied in a Phase 1 clinical trial in CLDN6-positive advanced or metastatic ovarian, endometrial and testicular cancers, assessing safety, tolerability, pharmacokinetics and anti-tumor activity. The company expects interim Phase 1a data for CTIM-76 in June 2026, highlighting a near-term clinical milestone for this program.
Context Therapeutics Inc. provided an updated corporate presentation outlining its strategy to build a leading T‑cell engager (TCE) pipeline for solid tumors and confirming an expected cash runway into mid‑2027. The company is advancing three CD3‑engaging bispecific antibodies: CTIM‑76 targeting Claudin 6, CT‑95 targeting mesothelin, and CT‑202 targeting Nectin‑4, all aimed at large relapse/refractory patient populations in ovarian, pancreatic, lung, bladder and other cancers.
CTIM‑76 is in an ongoing Phase 1a trial in CLDN6‑positive ovarian, endometrial and testicular cancers. As of October 2025, 12 heavily pretreated patients were enrolled, with linear pharmacokinetics, dose‑responsive T‑cell activity, no dose‑limiting toxicities, no cytokine release syndrome above Grade 1, and one confirmed partial response showing an 85% tumor reduction in platinum‑resistant ovarian cancer; interim Phase 1a data are anticipated in June 2026.
CT‑95 started a Phase 1a/1b dose‑escalation study in multiple mesothelin‑expressing tumors, with interim Phase 1a data expected in September 2026. CT‑202 remains preclinical, using pH‑dependent, avidity‑enhanced design to concentrate activity in the tumor microenvironment, with first patient dosing in a Phase 1 trial planned for the third quarter of 2026. Across the portfolio, preclinical models show selective tumor cell killing with efforts to reduce cytokine release and off‑tumor toxicity.
Context Therapeutics Inc. reports governance changes following a Delaware Court of Chancery ruling on a stockholder class action. On March 11, 2026, the court approved a stipulated judgment declaring charter provisions that set three-year director terms and removal only for cause invalid and unenforceable. The company filed a Certificate of Correction removing these provisions from its charter.
As a result, the current directors’ terms will expire at the 2026 annual meeting of stockholders, and directors may now be removed with or without cause by a majority of shares entitled to vote. The class action was dismissed with prejudice as to the plaintiff. The 2026 annual meeting is scheduled for June 24, 2026, with a record date of April 27, 2026, and the company plans to propose election of director nominees to one-year terms.
Context Therapeutics Inc. filed an agreement to resolve a Delaware stockholder class action by asking the court to invalidate two charter provisions that gave directors three-year terms and allowed removal only for cause. If the court approves the stipulated judgment, these governance provisions will be removed through a Certificate of Correction.
The case would then be dismissed with prejudice, and the company plans to hold its 2026 annual meeting of stockholders on June 24, 2026, with a record date of April 27, 2026. Stockholders must submit proposals or director nominations by 5:00 p.m. EDT on March 14, 2026, and any stockholders using universal proxy rules to solicit for alternate director nominees must give notice by April 13, 2026.
Context Therapeutics Inc. furnished an updated corporate presentation dated January 2026 for use in meetings with investors, analysts and other stakeholders. The presentation is provided as Exhibit 99.1 to this report and is incorporated by reference for informational purposes. The company states that the materials in Item 7.01 and Exhibit 99.1 are being furnished, not filed, meaning they are not subject to certain liability provisions of the Exchange Act and are not automatically incorporated into other Securities Act or Exchange Act filings.
Context Therapeutics (CNTX) announced pipeline updates alongside its third-quarter 2025 communication. The company highlighted progress in three bispecific T cell engager programs across early development.
CTIM-76 (CLDN6 x CD3) Phase 1: 12 patients enrolled as of October 30, 2025; currently in Cohort 5 with a 140 mcg priming dose and 560 mcg full dose. Preliminary signs of anti-tumor activity, including an ongoing RECIST response, were observed beginning at Cohort 3. No CRS greater than Grade 1, no dose-limiting toxicities, and the maximum tolerated dose has not been reached. The company plans updated interim Phase 1a data and Phase 1b dose selection in the second quarter of 2026.
CT-95 (MSLN x CD3) Phase 1: 6 patients enrolled; in Cohort 3 with a 0.18 µg/kg priming dose and 0.6 µg/kg full dose. Based on preclinical work, target dose exposure is projected starting at Cohort 4. No CRS greater than Grade 2, no DLTs, and no MTD reached. Initial Phase 1a data are anticipated mid‑2026.
CT-202 (Nectin‑4 x CD3): preclinical program expects regulatory filings to support a first‑in‑human trial in the second quarter of 2026.
Context Therapeutics Inc. amended its at-the-market equity program with Leerink Partners, allowing the company to offer and sell common stock with an aggregate offering price of up to $75.0 million as of October 24, 2025, exclusive of shares previously sold under its prior ATM prospectus.
Under the prior ATM prospectus dated December 2, 2024, the company sold 14,705,882 shares for an aggregate offering price of approximately $15.0 million. The amended program will use the company’s Form S-3 (File No. 333-283037), declared effective on November 14, 2024, as supplemented on October 24, 2025.
Leerink Partners will receive a commission of up to 3.0% of gross proceeds. Context plans to use any net proceeds for research and development, working capital, and general corporate purposes, which may include asset acquisitions. The company also suspended and terminated the prior ATM sales prospectus.
Context Therapeutics reported that it has regained compliance with Nasdaq’s Minimum Bid Price Rule. Nasdaq notified the company on October 17, 2025 that the closing bid price of CNTX common stock has been at $1.00 per share or greater for the last 10 consecutive business days, and that the matter is closed.
The company previously received deficiency notices and an extension to regain compliance until February 23, 2026. This update confirms CNTX remains listed on Nasdaq under the rule.
Context Therapeutics Inc. reported that Nasdaq has granted the company an additional 180 days, until February 23, 2026, to regain compliance with Nasdaq’s minimum bid price requirement of $1.00 per share under Listing Rule 5550(a)(2). This follows an earlier notice received on February 27, 2025, that the company’s stock had traded below the $1.00 minimum closing bid price for 30 consecutive business days.
The new extension does not immediately affect the listing or trading of the company’s common stock on Nasdaq. Context Therapeutics plans to monitor its share price and is evaluating options to regain compliance, including a potential reverse stock split, but it notes there is no assurance it will meet the requirement by the extended deadline.